Real-World Leqembi Patients Showed 76% Lower Rate of Reaching Moderate Alzheimer's in Company Data Lacking a Placebo Group
Company data from 560 U.S. Leqembi patients found a lower three-year rate of progression to moderate or severe Alzheimer's, but the nonrandomized study lacked a placebo group.
Medical Daily ·